|
Not only do we believe that Nuvilex (OTCQB – NVLX) is attractive at current levels but we believe that the stock will make another big run this spring based on fundamental, catalytic, and technical reasons.
...
... greatest financial incentive to say whatever they need to, in order to destroy a company’s market value, lest it rise. In the case of Nuvilex, Inc. (OTCQB—NVLX—Spec Buy), a stock that rose from ...
... NUVILEX, INC. (OTC:QB – NVLX - $0.1315)
Price Target: $0.75
Rating: Speculative Buy
COMPANY SNAPSHOT
INVESTMENT HIGHLIGHTS
...
... changed its stance toward broad and widespread use cannabis. Driven by its own steps in recent weeks, Nuvilex, Inc.’s (OTCQB – NVLX - $0.12 – Spec Buy) medical marijuana initiatives may take center stage ...
... treatments to help cope with the disease, the new technology platform acquired by Nuvilex, Inc. (OTCQB – NVLX - $0.13 – Speculative Buy) may prove to be one of the breakthrough treatments in the space ...
... the merrier.” With a presence in disparate but potentially related markets, Nuvilex, Inc. (OTCQB – NVLX - $0.1349 – Spec Buy) is a triple threat that offers investors huge potential. With home run potential ...
Yesterday’s landmark announcement by Nuvilex Inc. (OTCQB – NVLX) likely assures that the company will receive a future boost in its overall valuation. Nuvilex has acquired the exclusive worldwide rights ...
In a year where there have been quite a few misfires in the small biotech world, Nuvilex, Inc. (OTCQB – NVLX - $0.139 – Spec Buy) is a shining star.
Investment and Company Research Opportunity ...
Savvy traders and followers of Nuvilex, Inc. (OTCQB – NVLX - $0.114 – Spec Buy), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases can sense ...
... While Nuvilex, Inc. (OTCQB – NVLX - $0.12 – Spec Buy) has only incrementally participated in this biotech stock decline, a series of upcoming milestone news events appear to be catalysts that should move ...
... such as Nuvilex Inc. (OTCQB – NVLX - $0.122).
Nearly 45,000 American are diagnosed with pancreatic cancer each year and with 38,000 deaths annually from the disease, pancreatic cancer is one of ...
The fourth quarter of the year is typically a good one for micro cap stocks due to seasonal and macro issues and this year should be no different. For Nuvilex, Inc. (OTCQB – NVLX - $0.12 – Spec Buy) shareholders, ...
For investors seeking a well-positioned mid-late stage biotechnology company, one may not need to go any further than Nuvilex, Inc. (OTCQB – NVLX - $0.135 – Spec Buy). The Company has nearly all of the ...
... two weeks, Nuvilex, Inc. (OTCQB – NVLX - $0.136 – Spec Buy) has executed huge steps that lead it onto the path that will result in the commencement of future Phase 3 clinical trials for pancreatic cancer, ...
... (OTCQB – NVLX - $01395 – Spec Buy). The Company released news that should have been received by investors as its most significant event to date, excluding the acquisition of rights to the ground-breaking ...
... (OTCQB – NVLX - $0.15 – Spec Buy), Nuvilex’s shares could enjoy a big boost once Bind’s IPO registration becomes effective.
Investment and Company Research Opportunity Research MICROCAP ...
One of the key catalysts in the near term for Nuvilex Inc. (OTCQB – NVLX - $0.146 – Spec Buy) is the establishment of a GMP (Good Manufacturing Practices) facility. The facility will be used to encapsulate ...
... Research MICROCAP HOT TOPICS
September 12, 2013
Nuvilex Forms Key Alliance with Industry Leader
Earlier this week, Nuvilex, Inc. (OTCQB – NVLX - $0.15 – Spec Buy) announced ...
... Inc. (NASDAQ – ONXX). by Amgen, Inc. (NASDAQ – AMGN). This recent buyout of a cancer treatment biotech by a major pharmaceutical firm bodes well for Nuvilex, Inc.’s (OTCQB – NVLX - $0.13 – ...
... report below.
Click here to receive future alerts directly in your inbox
NUVILEX, INC.
Biotech Valuations 101; NVLX Shares Are Cheap
Rob Goldman
[email protected] ...
... not uncommon that companies undergo multiple iterations. The mortality rate for these firms is very high as fewer than 20% survive to the Phase III clinical trials stage.
Nuvilex, Inc. (OTCQB – NVLX ...
... time and resources in order to stay on task and ensure optimum success. A situation such as the one described just occurred late last week with Nuvilex, Inc. (OTCQB – NVLX - $0.145 – NVLX). ...
... in Nuvilex, Inc. (OTCQB – NVLX - $0.15 - Spec Buy), so much attention was paid to technology, efficacy, and past clinical trial results that key changes within the Federal Drug Administration (FDA) seem ...
Lost in the dog days of August is the remarkable performance of Nuvilex, Inc. (OTCQB – NVLX) relative to the market and some of its key peers. Over the past ten days, while biotech stocks have largely ...
... (OTCQB – NVLX) announced via a shareholder update that it is in the process of securing similar rights for diabetes treatment as well. Funding has been committed and the closing is expected no later ...
... and the stock typically bounces back with a vengeance.
That has happened today with Nuvilex, Inc. (OTCQB – NVLX - $0.135) and investors who buy the stock are likely to be richly rewarded sooner than ...
Given the substantial costs to administer and conduct clinical trials exclusively in the U.S., it is likely that Nuvilex, Inc. (OTCQB – NVLX- $0.165 – Spec Buy) will elect to turn to overseas locations ...
... Nuvilex Inc.’s (OTCQB – NVLX - $0.17 – Spec Buy) live-cell encapsulation platform to treat patients with inoperable pancreatic cancer has garnered a great deal of press and accolades in the mainstream ...
... of sitting in the front row of a stage in Las Vegas to see a Rodney Dangerfield performance. Interestingly, the recent trading of some of Nuvilex Inc.’s (OTCQB – NVLX - $0.148 – Spec Buy) biotech sisters ...
... 2013
NUVILEX, INC. (OTC:QB – NVLX - $0.1495)
Price Target: $0.75
Rating: Speculative Buy
COMPANY SNAPSHOT
...
Considering the success of some of the programs in Israel in treating cancer patients with cannabis, Nuvilex Inc.’s (OTCQB – NVLX - $0.16 – Spec Buy) subsidiary, Medical Marijuana Sciences, Inc. may elect ...
... Is Ready To Lead The Medical Marijuana Research Arena
Just last week, Nuvilex, Inc. (OTCQB-NVLX-$0.171-Spec Buy) announced that it has acquired exclusive licenses associated with live-cell encapsulation-based ...
... reduced while upside potential moves front and center is Nuvilex, Inc. (OTCQB – NVLX - $0.1435– Spec Buy).
It was not too long ago that Nuvilex had what some might view as crippling real estate-related ...
... attention on devising more effective drug delivery methods. Perhaps these firms are following in the footsteps of Nuvilex, Inc. (OTCQB – NVLX - $0.15 – Spec Buy). Nuvilex is an international firm ...
... 17, 2013
Nuvilex Teaches Wall Street A Lesson In M&A
Last week, Nuvilex, Inc. (OTCQB – NVLX) announced that it now owns exclusive worldwide licenses associated with the live-cell encapsulation-based ...
This tactical acquisition gives NVLX everything it wanted, plus lower operating costs, and sets it up for 3rd party funding and clinical trials. Moreover, the pricing of the deal was 10% higher than the ...
... only to benefit entities engaged in medical marijuana research such as Medical Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. (OTCQB – NVLX - $0.11 – Spec Buy).
Moreover, a series of independent ...
... news. While new product development isn’t around the corner for Nuvilex, Inc. (OTCQB – NVLX - $0.105 – Spec Buy), the Company’s positioning and prospects in its breast cancer therapy studies remain outstanding. ...
... Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. (OTCQB – NVLX - $0.105 – Spec Buy), is in the formative stages of studying the effect of cannabidiol (CBD)-based cancer treatments which may ...
... it would come as no surprise if that offering incorporates the live-cell encapsulation therapy under development by Nuvilex, Inc. (OTCQB – NVLX - $0.107 – Spec Buy), and it would likely be worth billions ...
Although Nuvilex Inc. (OTCQB – NVLX - $0.11 – Spec Buy) is noted for its pancreatic cancer treatment studies, it may be that a combination of its canine mammary cancer trial and medical marijuana research ...
... all of the information regarding its live-cell encapsulation platform to treat pancreatic cancer and focuses on key data, it is easy to see that Nuvilex Inc. (OTCQB – NVLX - $0.11 – Spec Buy) has a real ...
...
June 12, 2013
Nuvilex is Beneficiary of Doctors’ Approach Toward Medical Marijuana
Earlier this year, Nuvilex, Inc. (OTCQB – NVLX - $0.1257 – Spec Buy) announced that it was entering the ...
The rare combination of large early stage investments in its pancreatic cancer R&D program and its Phase II clinical trial performance strongly bolsters Nuvilex’s (OTCQB – NVLX) prospects for approval ...
As Nuvilex Inc. (QTCQB - NVLX - $0.14 - Spec Buy) management can attest, scientists and clinicians often approach drug development and treatment very differently.
Investment and Company Research ...
... for broader medical marijuana availability in order to treat cancer patients, Nuvilex Inc. (OTCQB – NVLX- $0.1385 – Spec Buy - $0.75 Target) stands ready to engage in comprehensive research and development ...
Nuvilex Inc. (OTCQB – NVLX) could be viewed as a two-headed oncology treatment entity, rather than a firm with a single, proven oncology indication in its arsenal.
Investment ...
... Price
Rob Goldman [email protected]
Aaron Schweitzer [email protected]
May 28, 2013
NUVILEX, INC. (OTC:QB – NVLX - $0.14)
Price Target: ...
In recent months, a slew of activity has occurred in the nanomedicine, or nanobiotechnology industry, which bodes well for Nuvilex Inc. (OTCQB – NVLX), an international firm engaged in live-cell encapsulation ...
... May 21, 2013, Goldman Small Cap Research published an Article on Nuvilex, Inc. (OTCQB – NVLX). For your convenience, a copy of the article can be found below.
Please see previous NVLX reports ...
|
||
|
|
||